Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|June 1, 2014

BioPharm International

  • BioPharm International-06-01-2014
  • Volume 27
  • Issue 6

Handheld Analyzer Improves Accuracy

Author(s)Melanie Sena

Handheld Analyzer Improves Accuracy

Rigaku Raman Technologies’ handheld ramen analyzer, the Rigaku Progeny, is designed to deliver accurate materials identification and improve ease of use, adaptability, and reliability. The Progeny has a 1064 nm high-power excitation laser, which increases speed and sensitivity of analysis and minimizes fluorescence interferences. A 512-pixel detector delivers improved resolution, analytics, and signal-to-noise ratio for handling challenging mixture analyses. The sealed system (IP-68) guards against moisture and dust, enabling rugged warehouse use and easy cleaning while minimizing cross-contamination risk.

The ergonomic design and shape provide single-hand entry into industrial barrels/drums, allowing users to view the screen while the instrument is in a downward orientation. The Progeny’s customizable workflow software is 21 CFR Part 11 compliant and has a smart phone-inspired user interface allowing quick implementation of material ID methods.

Rigaku Raman Technologies


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.